FTL008.16是一种5t4 -条件4-1BB双特异性抗体,通过肿瘤定向t细胞活化有效增强抗肿瘤免疫。

IF 6.2 2区 医学 Q1 IMMUNOLOGY Oncoimmunology Pub Date : 2026-12-31 Epub Date: 2026-06-10 DOI:10.1080/2162402X.2026.2684136
Shuang Liu, Ziqing Ren, Yongyan Tu, Pengyu Chen, Yinglu Zhang, Shengyan Zhao, Xiaofeng Chen, Han Deng, Shuyun Yang, Feng Qu, Ming Zhang, Lantu Gou, Qing Li, Ying Huang, Fanxin Ma, Jinliang Yang
{"title":"FTL008.16是一种5t4 -条件4-1BB双特异性抗体,通过肿瘤定向t细胞活化有效增强抗肿瘤免疫。","authors":"Shuang Liu, Ziqing Ren, Yongyan Tu, Pengyu Chen, Yinglu Zhang, Shengyan Zhao, Xiaofeng Chen, Han Deng, Shuyun Yang, Feng Qu, Ming Zhang, Lantu Gou, Qing Li, Ying Huang, Fanxin Ma, Jinliang Yang","doi":"10.1080/2162402X.2026.2684136","DOIUrl":null,"url":null,"abstract":"<p><p>The clinical development of 4-1BB agonists for cancer immunotherapy has been constrained by dose-limiting toxicities, particularly hepatotoxicity. To overcome this challenge, we developed FTL008.16, a novel bispecific antibody targeting 4-1BB (CD137) on T cells and the tumor-associated antigen 5T4. FTL008.16 is a human IgG1 antibody bearing an effector-deficient Fc region that specifically binds 4-1BB at an epitope overlapping with that of its natural ligand (4-1BBL), potentially mimicking physiological 4-1BBL-mediated co-stimulation. As demonstrated through <i>in vitro</i> reporter assays and primary cell-based systems, FTL008.16 elicits dose-dependent 4-1BB activation strictly contingent on 5T4 engagement, enhancing T-cell proliferation, cytokine secretion, and tumor cell lysis, thereby demonstrating potent antitumor efficacy in preclinical models. <i>In vivo</i>, FTL008.16 exhibited superior efficacy over a conventional anti-4-1BB monoclonal antibody, suppressing established tumors in both CT26 and MC38 models, with complete regression observed in CT26 tumors. In cynomolgus monkeys, FTL008.16 demonstrated an excellent safety profile, with no elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) observed even at 50 mg/kg. Importantly, this 5T4-restricted activation mechanism confines immune stimulation to the tumor microenvironment, thereby circumventing the systemic toxicity associated with conventional 4-1BB agonists. Collectively, these findings establish FTL008.16 as a conditionally active immunotherapeutic agent that successfully achieves both robust antitumor efficacy and a favorable safety profile.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2684136"},"PeriodicalIF":6.2000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271331/pdf/","citationCount":"0","resultStr":"{\"title\":\"FTL008.16, a 5T4-Conditional 4-1BB bispecific antibody, potently enhances antitumor immunity via tumor-directed t-cell activation.\",\"authors\":\"Shuang Liu, Ziqing Ren, Yongyan Tu, Pengyu Chen, Yinglu Zhang, Shengyan Zhao, Xiaofeng Chen, Han Deng, Shuyun Yang, Feng Qu, Ming Zhang, Lantu Gou, Qing Li, Ying Huang, Fanxin Ma, Jinliang Yang\",\"doi\":\"10.1080/2162402X.2026.2684136\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The clinical development of 4-1BB agonists for cancer immunotherapy has been constrained by dose-limiting toxicities, particularly hepatotoxicity. To overcome this challenge, we developed FTL008.16, a novel bispecific antibody targeting 4-1BB (CD137) on T cells and the tumor-associated antigen 5T4. FTL008.16 is a human IgG1 antibody bearing an effector-deficient Fc region that specifically binds 4-1BB at an epitope overlapping with that of its natural ligand (4-1BBL), potentially mimicking physiological 4-1BBL-mediated co-stimulation. As demonstrated through <i>in vitro</i> reporter assays and primary cell-based systems, FTL008.16 elicits dose-dependent 4-1BB activation strictly contingent on 5T4 engagement, enhancing T-cell proliferation, cytokine secretion, and tumor cell lysis, thereby demonstrating potent antitumor efficacy in preclinical models. <i>In vivo</i>, FTL008.16 exhibited superior efficacy over a conventional anti-4-1BB monoclonal antibody, suppressing established tumors in both CT26 and MC38 models, with complete regression observed in CT26 tumors. In cynomolgus monkeys, FTL008.16 demonstrated an excellent safety profile, with no elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) observed even at 50 mg/kg. Importantly, this 5T4-restricted activation mechanism confines immune stimulation to the tumor microenvironment, thereby circumventing the systemic toxicity associated with conventional 4-1BB agonists. Collectively, these findings establish FTL008.16 as a conditionally active immunotherapeutic agent that successfully achieves both robust antitumor efficacy and a favorable safety profile.</p>\",\"PeriodicalId\":48714,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":\"15 1\",\"pages\":\"2684136\"},\"PeriodicalIF\":6.2000,\"publicationDate\":\"2026-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271331/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402X.2026.2684136\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/6/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402X.2026.2684136","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

4-1BB激动剂用于癌症免疫治疗的临床发展一直受到剂量限制性毒性,特别是肝毒性的限制。为了克服这一挑战,我们开发了FTL008.16,一种针对T细胞上的4-1BB (CD137)和肿瘤相关抗原5T4的新型双特异性抗体。FTL008.16是一种人IgG1抗体,具有效应蛋白缺陷Fc区,特异性结合4-1BB与其天然配体(4-1BBL)重叠的表位,可能模拟生理4-1BBL介导的共刺激。通过体外报告细胞试验和原代细胞系统证明,FTL008.16诱导剂量依赖性的4-1BB激活,严格依赖于5T4的参与,增强t细胞增殖、细胞因子分泌和肿瘤细胞裂解,从而在临床前模型中显示出强大的抗肿瘤功效。在体内,FTL008.16表现出优于传统抗4- 1bb单克隆抗体的疗效,在CT26和MC38模型中抑制已建立的肿瘤,在CT26肿瘤中观察到完全消退。在食蟹猴中,FTL008.16显示出极好的安全性,即使在50 mg/kg的剂量下,也没有观察到谷丙转氨酶(ALT)或天冬氨酸转氨酶(AST)的升高。重要的是,这种5t4限制性激活机制将免疫刺激限制在肿瘤微环境中,从而规避了与传统4-1BB激动剂相关的全身毒性。总的来说,这些发现表明FTL008.16是一种有条件活性的免疫治疗剂,成功地实现了强大的抗肿瘤功效和良好的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
FTL008.16, a 5T4-Conditional 4-1BB bispecific antibody, potently enhances antitumor immunity via tumor-directed t-cell activation.

The clinical development of 4-1BB agonists for cancer immunotherapy has been constrained by dose-limiting toxicities, particularly hepatotoxicity. To overcome this challenge, we developed FTL008.16, a novel bispecific antibody targeting 4-1BB (CD137) on T cells and the tumor-associated antigen 5T4. FTL008.16 is a human IgG1 antibody bearing an effector-deficient Fc region that specifically binds 4-1BB at an epitope overlapping with that of its natural ligand (4-1BBL), potentially mimicking physiological 4-1BBL-mediated co-stimulation. As demonstrated through in vitro reporter assays and primary cell-based systems, FTL008.16 elicits dose-dependent 4-1BB activation strictly contingent on 5T4 engagement, enhancing T-cell proliferation, cytokine secretion, and tumor cell lysis, thereby demonstrating potent antitumor efficacy in preclinical models. In vivo, FTL008.16 exhibited superior efficacy over a conventional anti-4-1BB monoclonal antibody, suppressing established tumors in both CT26 and MC38 models, with complete regression observed in CT26 tumors. In cynomolgus monkeys, FTL008.16 demonstrated an excellent safety profile, with no elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) observed even at 50 mg/kg. Importantly, this 5T4-restricted activation mechanism confines immune stimulation to the tumor microenvironment, thereby circumventing the systemic toxicity associated with conventional 4-1BB agonists. Collectively, these findings establish FTL008.16 as a conditionally active immunotherapeutic agent that successfully achieves both robust antitumor efficacy and a favorable safety profile.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncoimmunology
Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY
CiteScore
12.50
自引率
2.80%
发文量
276
审稿时长
24 weeks
期刊介绍: OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.
期刊最新文献
IL-37/IL-1R8 axis: a novel major mechanism of control at the interface between tumor and immune cells. A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in in vivo and ex vivo models. Single-cell landscape of peripheral and tumor-infiltrating immune cells in HPV-negative HNSCC. Unlocking the therapeutic potential of immuno-radiotherapy: insights from preclinical and clinical research. The LXRβ/NF-κB axis reprograms CAR-T cells to resist exhaustion in the tumor microenvironment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1